Clinical significance of N-terminal-probrain natriuretic peptide in hypertrophic cardiomyopathy
| Autor: | Haralambos Karvounis, Areti Hitoglou-Makedou, Sotirios Mochlas, Georgios Giannakoulas, Georgios K. Efthimiadis, Theodoros D. Karamitsos, Georgios E. Louridas, Haris Stefanidis, Anastasia Mitakidou, Georgios Parcharidis, Ioannis H. Styliadis |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent medicine.drug_class Cardiomyopathy Asymptomatic Cohort Studies Internal medicine Natriuretic Peptide Brain medicine Natriuretic peptide Humans Clinical significance cardiovascular diseases Aged Aged 80 and over Heart Failure Univariate analysis Models Statistical business.industry Hypertrophic cardiomyopathy Cardiomyopathy Hypertrophic Middle Aged medicine.disease Protein Structure Tertiary Cardiac surgery Echocardiography Heart failure Cardiology Regression Analysis Female medicine.symptom Cardiology and Cardiovascular Medicine business hormones hormone substitutes and hormone antagonists |
| Zdroj: | Heart and Vessels. 22:322-327 |
| ISSN: | 1615-2573 0910-8327 |
| DOI: | 10.1007/s00380-007-0976-y |
| Popis: | N-Terminal-probrain natriuretic peptide (NT-proBNP) plasma levels are elevated in patients with congestive heart failure. Published data concerning the utility of NT-proBNP in hypertrophic cardiomyopathy (HCM) are lacking. Our aim was to evaluate the clinical significance of NT-proBNP in patients with HCM. A blood sample was collected for plasma NT-proBNP measurement from 43 consecutive patients with documented HCM. NT-proBNP was measured using a chemiluminescent immunoassay kit (Roche Diagnostics) on an Elecsys 2010 analyzer. Median value of NT-proBNP was 219 pg/ml (range 8-3 045 pg/ml) in NYHA class I patients, 698 pg/ml (125-2 463 pg/ml) in NYHA class II patients, and 2 683 pg/ml (131-11 542 pg/ml) in NYHA class III and IV patients. NT-proBNP plasma levels were significantly higher across the severity of functional limitation (i.e., NYHA class classification) (P = 0.002). NT-proBNP levels were significantly higher in female than male (P = 0.034), in referral vs nonreferral patients (P = 0.004), in symptomatic vs asymptomatic patients (P = 0.020), in patients with basal subaortic gradient >or=30 mmHg (P = 0.001) and in the patients who were on cardioactive medication (P = 0.010). In univariate analysis NT-proBNP was significantly correlated with age (P < 0.001), left ventricular maximum wall thickness (P = 0.001), left atrial size (P = 0.019), and subaortic gradient >or=30 mmHg (P < 0.001). In multivariate regression analysis, age (P < 0.001), maximum wall thickness (P = 0.007), and gradient >or=30 mmHg (P = 0.027) were independently associated with NT-proBNP levels. Our data support the idea that measurement of plasma NT-proBNP levels in HCM patients is useful to assess their clinical status, especially the severity of hypertrophy and the presence of obstruction, although age must be taken into account. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink